Reinventing the Gene Vaccine com Andrew Geall

https://www.youtube.com/watch?v=cesLJwOePMk

Summary

TL;DR — Andrew Geall, a pioneer in mRNA vaccine delivery systems, discusses his extensive career journey and the development of self-amplifying RNA (saRNA) vaccines. He highlights the evolution of RNA vaccine technology, from early challenges to its current prominence, emphasizing the importance of scalable delivery systems and manufacturing processes.

Key points

• Geall's career spans over two decades, with significant contributions to drug delivery systems and mRNA vaccine platforms at companies like Novartis, Precision Nano Systems, and currently, Replicate Biosciences.

• He details the technical hurdles in developing RNA vaccines, including challenges in RNA synthesis, delivery via lipid nanoparticles (LNPs), and achieving competitive efficacy against conventional technologies.

• The presentation covers the journey of self-amplifying RNA (saRNA) vaccines, which offer potential advantages like lower doses and improved durability compared to linear mRNA.

• Geall showcases the rapid development and manufacturing capabilities for RNA vaccines, particularly highlighted during the COVID-19 pandemic, and discusses ongoing efforts to optimize vector design and production.

• He touches upon the potential of RNA technology for various applications beyond infectious diseases, including gene therapy and cancer vaccines, and the importance of antigen discovery.

Takeaway — The development of RNA vaccines is a complex, iterative process that has overcome significant scientific and manufacturing challenges, paving the way for potentially more effective and rapidly deployable vaccines and therapies.